Document is current

Article History

Accepted: 18 September 2023

First Online: 5 October 2023

Declarations

:

: As this manuscript reports on the proceedings of a conference, rather than a research study, ethical approval was not sought. Instead, explicit written permission was sought and obtained from all presenters featured in this manuscript. These permissions covered the exact text describing their presentation and any images or photographs reproduced.

: The authors sought and obtained written consent from all VARN2022 presenters featured in this article. Specifically, this consent pertained to the exact wording that is used to describe each project and, where applicable, for the publication of figures and photographs in an open-access publication.

: TU is a consultant for the Sabin Vaccine Institute (Sabin); and KLH, TS, CH, NB, MD and SK are Sabin employees. ED is the VARN chair; and BD, AMK, RL, RQ, FEK and HS were members of the VARN Conference Planning Committee and served as moderators and presenters at VARN2022. RK was the VARN2022 keynote speaker. BD, AMK, RL, FEK and RQ have received Sabin funding to conduct research. HS has previously received funding from vaccine manufactures for investigator driven research and for consultancy fees.